Management of transthyretin amyloidosis

A Condoluci, M Théaudin… - Swiss medical …, 2021 - research-collection.ethz.ch
Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of
transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical …

[PDF][PDF] Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survival

A Tubben, HLA Nienhuis, P van der Meer - Eur J Heart Fail, 2023 - research.rug.nl
In 2018 the results of the Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-
ACT) were published. 1 In this international, multicentre, double-blind, placebo-controlled …

Ser77Tyr transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features

A Dori, M Arad, Y Wasserstrum, A Pollak… - Annals of Clinical …, 2023 - Wiley Online Library
Objective Amyloidosis due to the transthyretin Ser77Tyr mutation (ATTRS77Y) is a rare
autosomal‐dominant disorder, characterized by carpal‐tunnel syndrome, poly‐and …

A szívamyloidosis diagnosztikájának és terápiájának aktualitásai: Az ESC Myocardial and Pericardial Diseases Munkacsoportjának 2021-es position statementje …

H Takács, V Nagy, G Rácz, Á Kormányos… - Cardiologia …, 2022 - real.mtak.hu
A szívamyloidosis egy súlyos, progresszív, infiltratív betegség, amelyet amiloidfibrillumok
szívizomban való lerakódása okoz. Hátterében általában hematológiai, krónikus …

[PDF][PDF] Advances in understanding, diagnosis and targeting ATTR cardiomy-opathy: a review

M Kulak, M Lang, M Waśniewski… - Eur J Transl Clin …, 2024 - ejtcm.gumed.edu.pl
Transthyretin amyloidosis (ATTR) manifests as wild-type (ATTRwt) and hereditary/mutant
(ATTRv) forms and can lead to heart failure due to cardiac amyloidopathy. Diagnosing …